MedTrace Logo

FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents

NCT02055586 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2020-09-18

No results posted yet for this study

Summary

This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with metastatic solid tumors receiving treatment that blocks blood flow to the tumor. Diagnostic procedures, such as FLT-PET/MRI, may help measure a patient's response earlier during treatment.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

OTHER

fluorine F 18 fluorothymidine

Undergo FLT-PET/MRI

DEVICE

positron emission tomography

Undergo FLT-PET/MRI

DEVICE

magnetic resonance imaging

Undergo FLT-PET/MRI

Sponsors & Collaborators

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Norbert Avril · Case Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-22
Primary Completion
2017-11-27
Completion
2017-12-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02055586 on ClinicalTrials.gov